18 June 2013
Keywords: Lung cancer, Individualized chemotherapy, NSCLC, In vitro HDRA
Article | 03 September 2010
Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 September 2010
2 September 2010
© 2013 thepharmaletter.com